PCLO.X
Recent Headlines
- PharmaCielo Announces Closing of Overnight Marketed Equity Offering for Gross Proceeds of $13.5 Million
- PharmaCielo Provides Corporate Update
- IIROC Trading Resumption - PCLO.WT
- Mexico Votes to Advance Recreational Cannabis Legalization - PharmaCielo Mexico Positioned to Become a Preferred Supplier
- IIROC Trading Resumption - PCLO
- PharmaCielo Ltd. Announces Upsize and Pricing of Overnight Marketed Equity Offering
- IIROC Trading Halt - PCLO
- PharmaCielo Ltd. Announces Overnight Marketed Equity Financing
- PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate
- PharmaCielo Provides Update on GMP Compliance Process
- PharmaCielo Announces Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity
- PharmaCielo Enters Strategic Alliance to Provide Pre-Tested and Insured Product to Customers in the U.S. Market
- PharmaCielo Receives Approximately CDN$3.0 Million in Non-Dilutive Funding from Colombian State-Owned Banco Agrario
- PharmaCielo Welcomes Landmark United Nations Decision to Remove Cannabis from Narcotic Drugs List
- PharmaCielo Announces Grant of Stock Options
- PharmaCielo Ltd.'s (CVE:PCLO) Path To Profitability
- PharmaCielo Ltd. Announces New Leadership
- PharmaCielo Announces Financial Results for the Third Quarter Ended September 30, 2020
- PharmaCielo Achieves Good Agricultural and Collection Practices (GACP) Designation
- PharmaCielo Announces Closing of $10M Private Placement
- PharmaCielo Mexico Salutes Mexican Senate for Advancing Cannabis Legalization
- PharmaCielo Enters U.K. Market with 500kg Initial Shipment to Established Manufacturer and Distributor - Reaches 2021 Agreement
- PharmaCielo to Hold Conference Call to Review Third Quarter 2020 Financial Results
- PharmaCielo to Participate in 2020 Cowen Boston Cannabis Conference
- PharmaCielo Begins Harvest of High-THC Cultivars for Extract Export
- PharmaCielo Announces Upsizing of Private Placement Offering
- PharmaCielo Ltd. Expands Board Depth and Expertise with Appointment of Marc Lustig as Lead Director and Strengthens Capital Position with Private Placement Offering
- PharmaCielo to Participate in Cantor Fitzgerald Latin America Cannabis Seminar
- PharmaCielo Declared 'Project of National Strategic Interest' by Government of Colombia
- PharmaCielo Expands Portfolio of Cannabis Extracts to Meet Global B2B Medical-Grade Market Demand
- How Much Did PharmaCielo's(CVE:PCLO) Shareholders Earn From Share Price Movements Over The Last Year?
- PharmaCielo Announces Financial Results for the Second Quarter Ended June 30, 2020 and Provides Operational Update
- PharmaCielo to Hold Conference Call to Review Second Quarter 2020 Financial Results
- PharmaCielo Increases Cannabis Cultivation Through External Contractor to Meet Market Demand for Medicinal Extracts
- Most Prolific Short Sellers Amid Covid and the Rise of Robinhood Traders
- PharmaCielo Receives Colombian Government Authorization for 10 Tonnes of High-THC Cultivation and Extract Production for Export
- PharmaCielo Ltd. Closes $4.6 Million Bought Deal Offering
- PharmaCielo Ltd. Files Final Prospectus for $4 Million Bought Deal Offering
- PharmaCielo Ltd. Announces $4,000,000 Bought Deal Public Offering
- Analysts Have Been Trimming Their PharmaCielo Ltd. (CVE:PCLO) Price Target After Its Latest Report
- PharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2020 and Provides Operational Update
- PharmaCielo Ltd. Obtains Final Receipt for Short Form Prospectus
- PharmaCielo Welcomes Dr. Claudia Jiménez to Board of Directors
- PharmaCielo Adds Experienced Senior Leader to Executive Team
- These Analysts Just Made An Downgrade To Their PharmaCielo Ltd. (CVE:PCLO) EPS Forecasts
- Analysts Have Lowered Expectations For PharmaCielo Ltd. (CVE:PCLO) After Its Latest Results
- TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against PharmaCielo Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2019
- PharmaCielo Provides Details for Fourth Quarter and Year-End 2019 Results Conference Call
- PharmaCielo Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in PharmaCielo Ltd. to Contact the Firm